Abstract
The pathophysiology of non-Hodgkin’s lymphoma is still unknown. Many cytokines, including interleukin-10 (IL-10), play a role in the perpetuation of the disease. The aim of the study was to investigate the association of IL-10 gene promoter polymorphisms with non-Hodgkin lymphoma and to correlate with survival. Fifty patients with diffuse large B-cell lymphoma as well as 50 age- and sex-matched apparently healthy volunteers were genotyped for biallellic IL-10 gene promoter polymorphisms at positions −1082(A/G) and −3557(T/A) using polymerase chain reaction–restriction fragment length polymorphism. There were highly statistically significant differences between the two studied groups regarding results of IL-10 1082A/G polymorphism, for homozygous (GG) and heterozygous (AG) genotypes (p value <0.0001) but no statistically significant differences regarding homozygous (AA) genotype (p value = 0.7583). IL-10 3575T/A polymorphism revealed highly statistically significant differences between the two groups regarding homozygous (TT; p value <0.0001) and heterozygous (TA) genotypes (p value = 0.0007), but no significant difference found regarding homozygous (AA) genotype (p value = 0.1622). We did not find any associations between bad prognostic factors and any of the genotypes or alleles frequencies. Our results also reported that there was no impact of these polymorphisms on survival of lymphoma patients. IL-10 1082A/G and 3557T/A polymorphisms could be claimed as independent risk factors for susceptibility to lymphoma, regardless of any associated bad prognostic factors and without impact on overall survival.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Benjamin D, Knobloch TJ, Dayton MA (1992) Human B-cell interleukin 10: B-cell lines derived from patients with acquired immunodeficiency syndrome and Burkitt’s lymphoma constitutively secrete large quantities of interleukin-10. Blood 80(5):1289–1298
Berglund M, Thunberg U, Roos G et al (2005) The interleukin-10 gene promoter polymorphism (−1082) does not correlate with clinical outcome in diffuse large B-cell lymphoma. Blood 105(12):4894–4895
Bogunia-Kubik K, Mazur G, Wróbel T et al (2008) Interleukin-10 gene polymorphisms influence the clinical course of non-Hodgkin’s lymphoma. Tissue Antigens 71(2):146–150
Coiffier B, Gisselbrecht C, Herbrecht R et al (1989) LNH-84 regimen: a multi-center study of intensive chemotherapy in 737 patients with aggressive malignant lymphoma. J Clin Oncol 7(8):1018–1026
Cunningham LM, Chapman C, Dunstan R et al (2003) Polymorphisms in the interleukin 10 gene promoter are associated with susceptibility to aggressive non-Hodgkin’s lymphoma. Leuk Lymphoma 44(2):251–255
Domingo-Domènech E, Benavente Y, González-Barca E et al (2007) Impact of interleukin-10 polymorphisms (−1082 and −3575) on the survival of patients with lymphoid neoplasms. Haematologica 92(11):1475–1481
Fernberg P, Chang ET, Duvefelt K et al (2010) Genetic variation in chromosomal translocation breakpoint and immune function genes and risk of non-Hodgkin lymphoma. Canc Causes Contr 21(5):759–769
Gibson AW, Edberg JC, Wu J et al (2001) Novel single nucleotide polymorphisms in the distal IL-10 promoter affect IL-10 production and enhance the risk of systemic lupus erythematosus. J Immunol 166(6):3915–3922
Hulkkonen J, Pertovaara M, Antonen J et al (2001) Genetic association between interleukin-10 promoter region polymorphisms and primary Sjogren’s syndrome. Arthritis Rheum 44(1):176–179
Karin M, Greten FR (2005) NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol 5(10):749–759
Kube D, Hua TD, von Bonin F et al (2008) Effect of interleukin-10 gene polymorphisms on clinical outcome of patients with aggressive non-Hodgkin’s lymphoma: an exploratory study. Clin Canc Res 14(12):3777–3784
Lan Q, Zheng T, Rothman N et al (2006) Cytokine polymorphisms in the Th1/Th2 pathway and susceptibility to non-Hodgkin lymphoma. Blood 107(10):4101–4108
Lech-Maranda E, Baseggio L, Bienvenu J et al (2004) Interleukin-10 gene promoter polymorphisms influence the clinical outcome of diffuse large B-cell lymphoma. Blood 103(9):3529–3534
Loercher AE, Nash MA, Kavanagh JJ et al (1999) Identification of an IL-10-producing HLA-DR-negative monocyte subset in the malignant ascites of patients with ovarian carcinoma that inhibits cytokine protein expression and proliferation of autologous T cells. J Immunol 163(11):6251–6260
Moore KW, de Waal Malefyt R, Coffman RL et al (2001) Interleukin 10 and the interleukin receptor. Annu Rev Immunol 19:683–765
Moraes MO, Santos AR, Schonkeren JJ et al (2003) Interleukin-10 promoter haplotypes are differently distributed in the Brazilian versus the Dutch population. Immunogenetics 54(12):896–899
Mosmann TR (1994) Properties and functions of interleukin-10. Adv Immunol 56:1–26
Myers AM, Moore GE, Atkins CD (1993) A predictive model for aggressive non-Hodgkin’s lymphoma. The International non-Hodgkin’s Lymphoma Prognostic Factors Project. New Engl J Med 329(14):987–994
Oken MM, Creech RH, Tormey DC et al (1982) Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5(6):649–655
Oswald IP, Gazzinelli RT, Sher A et al (1992) IL-10 synergizes with IL-4 and TGF-beta to inhibit macrophage cytotoxic activity. J Immunol 148(11):3578–3582
Purdue MP, Lan Q, Kricker A et al (2007) Polymorphisms in immune function genes and risk of non-Hodgkin lymphoma: findings from the New South Wales non-Hodgkin Lymphoma Study. Carcinogenesis 28(3):704–712
Rasouli M, Kiany S, Behbin M (2008) Interleukin-10 gene polymorphisms and susceptibility to brucellosis in Iranian patients. Iran J Immunol 5(2):131–135
Rosenberg SA (1977) Validity of the Ann Arbor staging classification for the non-Hodgkin’s lymphomas. Canc Treat Rep 61(6):1023–1027
Rothman N, Skibola CF, Wang SS et al (2006) Genetic variation in TNF and IL10 and risk of non-Hodgkin lymphoma: a report from the InterLymph Consortium. Lancet Oncol 7(1):27–38
Salmaggi A, Eoli M, Corsini E et al (2000) Cerebrospinal fluid interleukin-10 levels in primary central nervous system lymphoma: a possible marker of response to treatment? Ann Neurol 47(1):137–138
Sato T, McCue P, Masuoka K et al (1996) Interleukin 10 production by human melanoma. Clin Canc Res 2(8):1383–1390
Turner DM, Williams DM, Sankaran D et al (1997) An investigation of polymorphism in the interleukin-10 gene promoter. Eur J Immunogenet 24(1):1–8
Wang SS, Cerhan JR, Hartge P et al (2006) Common genetic variants in proinflammatory and other immunoregulatory genes and risk for non-Hodgkin lymphoma. Canc Res 66(19):9771–9780
Wang SS, Cozen W, Cerhan JR et al (2007) Immune mechanisms in non-Hodgkin lymphoma: joint effects of the TNF G308A and IL10 T3575A polymorphisms with non-Hodgkin lymphoma risk factors. Canc Res 67(10):5042–5054
Westendorp RG, van Dunne FM, Kirkwood TB et al (2001) Optimizing human fertility and survival. Nat Med 7(8):873
Acknowledgements
We would like to express our gratitude to the nursing team of the hematology unit, nuclear medicine & oncology department, Faculty of Medicine, Cairo University for helping us in collecting samples from patients after giving their written informed consent.
Financial support
On behalf of authors, i confirm that our work did not receive any financial support.
Conflicts of interest
The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Sami, R.M., Nasr, A.S., Ibrahim, N.Y. et al. Association of IL-10 gene promoter polymorphisms and non-Hodgkin lymphoma in Egyptian patients, relation to susceptibility, correlation with survival. Comp Clin Pathol 21, 1407–1415 (2012). https://doi.org/10.1007/s00580-011-1307-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00580-011-1307-3